Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy”(2019/07/24)

Title:

NHRI technology, “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy” (abbreviated as “The Technology”) available for industry-academia collaboration technology licensing.

Description:

DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction.

Potential collaboration partner qualifications:

  1. be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
  2. better to have related experience and skills for developing The Technology
  3. better to have experience of international collaboration and clinical trial
  4. be willing to provide long-term investment

Registration:

Please contact to Mr. Hua-Hsuan Liang (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166#33206, E-mail: huahsuan@nhri.org.tw).

Other:

  1. If The Technology has been exclusively licensed, this announcement will automatically invalid.
  2. NHRI retains the right to modify and terminate this announcement.
  3. For detailed status of The Technology, please contact to the case officer.

Attachments:
I: Announcement
II: Licensing Proposal
III: Industry-Academia Collaboration Proposal

Comments are closed.